Status:
WITHDRAWN
Glucocorticoid Therapy for Acute Respiratory Distress Syndrome
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Acute Respiratory Distress Syndrome
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
Acute respiratory distress syndrome (ARDS) is a clinical syndrome of inflammatory lung injury characterized by increased pulmonary vascular permeability, loss of aerated lung tissue, severe hypoxemia ...
Eligibility Criteria
Inclusion
- Moderate to severe ARDS with a P/F ratio \< 200 mmHg
- On invasive mechanical ventilation
- The onset of ARDS \< 72 hours
Exclusion
- Age \<20 years
- Receiving systemic glucocorticoid therapy
- Uncontrolled gastrointestinal bleeding
- Terminal cancer
- Post-operation or with large wound
- Considered by the primary care doctor to be either definitely indicated or definitely contraindicated for glucocorticoid therapy
- Anticipating to receive chemotherapy and immunotherapy in 3 months
- Uncontrolled fungal infection
- Post solid organ or bone marrow transplant
- Severe influenza without anti-viral therapy
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05401812
Start Date
July 1 2022
End Date
April 30 2024
Last Update
March 18 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.